ArticleFrontiers in chemistry2026
Development and validation of a novel analytical method for related substances of resmetirom and identification of new degradation products.
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Resmetirom (MGL-3196), a highly selective thyroid hormone receptor β agonist, is indicated for treating adults with noncirrhotic nonalcoholic steatohepatitis (NASH) exhibiting moderate to advanced liver fibrosis. Related substances are critical factors that directly impact the safety and efficacy of the active pharmaceutical ingredient (API). Therefore, the quantitative detection of related substances in resmetirom is of particular importance. Methods: This study established a reverse-phase high-performance liquid chromatography (RP-HPLC) for the separation of resmetirom and its related substances. The analysis was performed using an Agilent 5 HC C Results: The method was validated according to International Conference on Harmonization (ICH) guidelines, and the results demonstrated that it possesses good specificity, stability, linearity, precision, repeatability, and robustness. Furthermore, a new degradation product, designated as imp-A, was generated under alkaline degradation conditions in this study. Its chemical structure was elucidated using nuclear magnetic resonance (NMR) and high-resolution mass spectrometry (HRMS), and this compound has been reported for the first time. Conclusion: The RP-HPLC method established in this study is capable of accurately and reliably separating and detecting resmetirom and its related substances. The method is simple to operate and yields dependable results, providing a practical and efficient analytical tool for the quality control of resmetirom and its formulations. This contributes to ensuring the safety and efficacy of the drug product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.